Abstract
Most cancer therapies are seldom effective by using one anticancer drug owing to refractory and resistance property of cancer tissues caused by multiple genetic alterations and molecular abnormalities. Despite great popularity of anticancer drug combination utilizations, the hidden rules behind scenarios emerge in new era of anticancer therapy. Most importantly, anticancer drug cocktails need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapy across the history. Possible future landscapes and drawbacks of current cancer drug combinative therapy are addressed and speculated.
Highlights
Cancer is a common disease that claims life about 7-10 million people annually in the world
Since few anticancer drug combinations modular have been subjected for mechanism investigations and highlighted into scientific principle discoveries, anticancer drug cocktail designs need to transform from empirical decision into science-guided modern predictive systems
Apart from manufacturing high effective and specificity anticancer or antimetastatic drugs [46,47,48,49,50,51], combinative utilizations of both antiproliferative drugs and antimetastatic drugs is supposed to be a useful paradigm for survival elongations of many advanced cancer patients
Summary
Cancer is a common disease that claims life about 7-10 million people annually in the world. Doxorubicin and Biz compounds could cooperate one and another in combating with drug-resistance and neoplasm metastasis [12,13,16,17] One of these modular and paradigms is possibly the combination of cytotoxic chemicals with biotherapies [8,9,10]. Apart from manufacturing high effective and specificity anticancer or antimetastatic drugs [46,47,48,49,50,51], combinative utilizations of both antiproliferative drugs (primary tumor) and antimetastatic drugs is supposed to be a useful paradigm for survival elongations of many advanced (late-staged) cancer patients. Since there are diversity in therapeutic efficacies, toxicities, mechanisms of action and therapeutic pathways by different anticancer drugs in individual cancer patients, may some other predictive or selective systems (such as drug sensitivity testing etc) be borrowed? Further information and future perspective will be given in the followings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
